Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Receivables (2016 - 2025)

Historic Receivables for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to $26.8 million.

  • Gyre Therapeutics' Receivables rose 2846.72% to $26.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.8 million, marking a year-over-year increase of 2846.72%. This contributed to the annual value of $28.9 million for FY2024, which is 9074.72% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' Receivables is $26.8 million, which was up 2846.72% from $25.3 million recorded in Q2 2025.
  • Over the past 5 years, Gyre Therapeutics' Receivables peaked at $28.9 million during Q4 2024, and registered a low of $564000.0 during Q1 2022.
  • For the 5-year period, Gyre Therapeutics' Receivables averaged around $12.6 million, with its median value being $15.2 million (2023).
  • Per our database at Business Quant, Gyre Therapeutics' Receivables crashed by 4512.53% in 2021 and then surged by 84257.43% in 2022.
  • Over the past 5 years, Gyre Therapeutics' Receivables (Quarter) stood at $1.8 million in 2021, then surged by 842.57% to $17.1 million in 2022, then decreased by 11.51% to $15.2 million in 2023, then surged by 90.75% to $28.9 million in 2024, then fell by 7.44% to $26.8 million in 2025.
  • Its Receivables was $26.8 million in Q3 2025, compared to $25.3 million in Q2 2025 and $22.5 million in Q1 2025.